Novel Use of Thalidomide in Recurrent Gastrointestinal Tract Bleeding in Patients with Left Ventricular Assist Devices: A Case Series

Heart Lung Circ. 2017 Oct;26(10):1101-1104. doi: 10.1016/j.hlc.2016.11.017. Epub 2016 Dec 23.

Abstract

Background: Bleeding is an important and common complication of left ventricular assist devices (LVADs). One of the common causes of gastrointestinal bleeding is arteriovenous malformations. However, the source of bleeding is often hard to identify. Thalidomide is efficacious in treatment of gastrointestinal (GI) bleeding in non-LVAD patients. We report our experience of the use of thalidomide in the treatment of GI bleeding in four patients with LVAD.

Method and results: Four patients who had recurrent GI bleeding from May 2009 to December 2014 were started on thalidomide. All of them responded to treatment and had no further gastrointestinal bleeding while on thalidomide. One patient developed constipation, requiring thalidomide to be stopped. Another patient developed symptomatic neuropathy, that resolved with reduction of dosage.

Conclusion: Thalidomide appears safe and efficacious in LVAD patients with recurrent gastrointestinal bleeding.

Keywords: Gastrointestinal haemorrhage; Thalidomide; Ventricular assist devices.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / administration & dosage
  • Cardiomyopathies / surgery*
  • Dose-Response Relationship, Drug
  • Gastrointestinal Hemorrhage / drug therapy*
  • Gastrointestinal Hemorrhage / etiology
  • Heart-Assist Devices / adverse effects*
  • Humans
  • Male
  • Middle Aged
  • Retrospective Studies
  • Thalidomide / administration & dosage*
  • Treatment Outcome

Substances

  • Angiogenesis Inhibitors
  • Thalidomide